Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with
GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response
to other drugs.